PRTN3 and rheumatoid arthritis: A lower proportion of patients were seropositive (75–77% RF positive, 72–75% ACPA positive and 67–70% double positive across treatment groups) than in RA-BEGIN and RA-BEAM, and hsCRP levels were 5–6 times ULN.